Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Autoantibodies and Their Clinical Significance in a Black Vitiligo Population

Autoantibodies and Their Clinical Significance in a Black Vitiligo Population Abstract • The frequency of autoantibodies was determined in 70 black vitiligo patients and controls. Both groups were screened for antithyroid, antinuclear, antigastric parietal cell, anti-smooth muscle cell, and antimitochondrial autoantibodies. The significance of autoantibodies was determined in vitiligo patients by correlating their presence or absence with various clinical features of the patients. The overall frequencies of autoimmune and endocrine diseases were also assessed in vitiligo patients, controls, and their respective families. Vitiligo patients had an increased frequency of antithyroid antibodies and an increased frequency of autoimmune and/or endocrine diseases. These diseases included, especially, hyperthyroidism, hypothyroidism, and alopecia areata. Autoantibody-positive vitiligo patients had an increased frequency of firstand second-degree relatives having autoimmune and/or endocrine diseases. These findings tend to support an autoimmune cause of vitiligo in black patients. (Arch Dermatol 1983;119:300-303) References 1. Allison JR, Curtis AC: Vitiligo and pernicious anemia . Arch Dermatol 1955;72:407-408.Crossref 2. McGregor BC, Katz HI, Doe RP: Vitiligo and multiple glandular insufficiencies . JAMA 1972;219:724-725.Crossref 3. Ochi Y, DeGroot LJ: Vitiligo in Graves' disease . Ann Intern Med 1969;71:935-940.Crossref 4. Dawber RPR: Vitiligo in mature-onset diabetes mellitus . Br J Dermatol 1968;80:275-278.Crossref 5. Bor S, Feiwel M, Chanarin I: Vitiligo and its aetiological relationship to organ-specific autoimmune disease . Br J Dermatol 1969;81:83-88.Crossref 6. Dawber RPR: Clinical associations of vitiligo . Postgrad Med J 1970;46:276-277.Crossref 7. Grunnet I, Howitz J, Reymann F, et al: Vitiligo and pernicious anemia . Arch Dermatol 1970;101:82-85.Crossref 8. Cunliffe WJ, Hall R, Newell DJ: Vitiligo, thyroid disease and autoimmunity . Br J Dermatol 1968;80:135-139.Crossref 9. Harsoulis P, Kanakoudi-Tsakalidis F, Vyzantiadis A, et al: Autoimmunity and vitiligo . Arch Dermatol 1978;114:1554.Crossref 10. Betterle C, Franco Del Preta G, Peserico A, et al: Autoantibodies in vitiligo . Arch Dermatol 1976;112:1328.Crossref 11. Brastoff J, Bor S, Feiwel M: Autoantibodies in patients with vitiligo . Lancet 1969;2:177-178.Crossref 12. Barsky S, Knapp DP, Levine M, et al: Vitiligo in a black population . Arch Dermatol 1979;115:225.Crossref 13. Mosher DB, Fitzpatrick TB, Ortonne JP: Abnormalities of pigmentation , in Fitzpatrick TB, Eisen AZ, Wolff C, et al (eds): Dermatology in General Medicine . New York, McGraw-Hill Book Co, 1979, pp 568-629. 14. Parrish JA, Fitzpatrick TB, Shea C, et al: Photochemotherapy of vitiligo . Arch Dermatol 1976;112:1531-1534.Crossref 15. Pathak MA, Mosher DB, Fitzpatrick TB, et al: Relative effectiveness of three psoralens and sunlight in repigmentation of 365 vitiligo patients, abstracted . J Invest Dermatol 1980;74:252. 16. Fulton JE Jr, Leyden J, Papa C: Treatment of vitiligo with topical methoxalen and blacklite . Arch Dermatol 1969;100:224-229.Crossref 17. Von Langhof H, Feverstein M, Schabinski G: Melaninantik or per beldunj bei vitiligo . Hautarzt 1965;5:209-212. 18. Hertz KC, Gazze LA, Kirkpatrick CH, et al: Autoimmune vitiligo: Detection of antibodies to melanin-producing cells . N Engl J Med 1977;297:634-637.Crossref 19. Betterle C, Peserico A, Bersani G: Vitiligo and autoimmune polyendocrine deficiencies with autoantibodies to melanin-producing cells . Arch Dermatol 1979;115:364.Crossref 20. Howanitz N, Nordlund J, Lerner A, et al: Antibodies to melanocytes: Occurrence in patients with vitiligo and chronic mucocutaneous candidiasis . Arch Dermatol 1981;117:705-708.Crossref 21. Dawber RPR: Clinical associations of vitiligo . Postgrad Med J 1970;46:276-277.Crossref 22. Lerner AB, Nordlund JJ: Vitiligo: What is it? Is it important? JAMA 1978;239:1183-1187.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Autoantibodies and Their Clinical Significance in a Black Vitiligo Population

Loading next page...
 
/lp/american-medical-association/autoantibodies-and-their-clinical-significance-in-a-black-vitiligo-nIbTG0y3Kp
Publisher
American Medical Association
Copyright
Copyright © 1983 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1983.01650280028010
Publisher site
See Article on Publisher Site

Abstract

Abstract • The frequency of autoantibodies was determined in 70 black vitiligo patients and controls. Both groups were screened for antithyroid, antinuclear, antigastric parietal cell, anti-smooth muscle cell, and antimitochondrial autoantibodies. The significance of autoantibodies was determined in vitiligo patients by correlating their presence or absence with various clinical features of the patients. The overall frequencies of autoimmune and endocrine diseases were also assessed in vitiligo patients, controls, and their respective families. Vitiligo patients had an increased frequency of antithyroid antibodies and an increased frequency of autoimmune and/or endocrine diseases. These diseases included, especially, hyperthyroidism, hypothyroidism, and alopecia areata. Autoantibody-positive vitiligo patients had an increased frequency of firstand second-degree relatives having autoimmune and/or endocrine diseases. These findings tend to support an autoimmune cause of vitiligo in black patients. (Arch Dermatol 1983;119:300-303) References 1. Allison JR, Curtis AC: Vitiligo and pernicious anemia . Arch Dermatol 1955;72:407-408.Crossref 2. McGregor BC, Katz HI, Doe RP: Vitiligo and multiple glandular insufficiencies . JAMA 1972;219:724-725.Crossref 3. Ochi Y, DeGroot LJ: Vitiligo in Graves' disease . Ann Intern Med 1969;71:935-940.Crossref 4. Dawber RPR: Vitiligo in mature-onset diabetes mellitus . Br J Dermatol 1968;80:275-278.Crossref 5. Bor S, Feiwel M, Chanarin I: Vitiligo and its aetiological relationship to organ-specific autoimmune disease . Br J Dermatol 1969;81:83-88.Crossref 6. Dawber RPR: Clinical associations of vitiligo . Postgrad Med J 1970;46:276-277.Crossref 7. Grunnet I, Howitz J, Reymann F, et al: Vitiligo and pernicious anemia . Arch Dermatol 1970;101:82-85.Crossref 8. Cunliffe WJ, Hall R, Newell DJ: Vitiligo, thyroid disease and autoimmunity . Br J Dermatol 1968;80:135-139.Crossref 9. Harsoulis P, Kanakoudi-Tsakalidis F, Vyzantiadis A, et al: Autoimmunity and vitiligo . Arch Dermatol 1978;114:1554.Crossref 10. Betterle C, Franco Del Preta G, Peserico A, et al: Autoantibodies in vitiligo . Arch Dermatol 1976;112:1328.Crossref 11. Brastoff J, Bor S, Feiwel M: Autoantibodies in patients with vitiligo . Lancet 1969;2:177-178.Crossref 12. Barsky S, Knapp DP, Levine M, et al: Vitiligo in a black population . Arch Dermatol 1979;115:225.Crossref 13. Mosher DB, Fitzpatrick TB, Ortonne JP: Abnormalities of pigmentation , in Fitzpatrick TB, Eisen AZ, Wolff C, et al (eds): Dermatology in General Medicine . New York, McGraw-Hill Book Co, 1979, pp 568-629. 14. Parrish JA, Fitzpatrick TB, Shea C, et al: Photochemotherapy of vitiligo . Arch Dermatol 1976;112:1531-1534.Crossref 15. Pathak MA, Mosher DB, Fitzpatrick TB, et al: Relative effectiveness of three psoralens and sunlight in repigmentation of 365 vitiligo patients, abstracted . J Invest Dermatol 1980;74:252. 16. Fulton JE Jr, Leyden J, Papa C: Treatment of vitiligo with topical methoxalen and blacklite . Arch Dermatol 1969;100:224-229.Crossref 17. Von Langhof H, Feverstein M, Schabinski G: Melaninantik or per beldunj bei vitiligo . Hautarzt 1965;5:209-212. 18. Hertz KC, Gazze LA, Kirkpatrick CH, et al: Autoimmune vitiligo: Detection of antibodies to melanin-producing cells . N Engl J Med 1977;297:634-637.Crossref 19. Betterle C, Peserico A, Bersani G: Vitiligo and autoimmune polyendocrine deficiencies with autoantibodies to melanin-producing cells . Arch Dermatol 1979;115:364.Crossref 20. Howanitz N, Nordlund J, Lerner A, et al: Antibodies to melanocytes: Occurrence in patients with vitiligo and chronic mucocutaneous candidiasis . Arch Dermatol 1981;117:705-708.Crossref 21. Dawber RPR: Clinical associations of vitiligo . Postgrad Med J 1970;46:276-277.Crossref 22. Lerner AB, Nordlund JJ: Vitiligo: What is it? Is it important? JAMA 1978;239:1183-1187.Crossref

Journal

Archives of DermatologyAmerican Medical Association

Published: Apr 1, 1983

References